Pfizer is delving deeper into cancer research with a roughly $11.4 billion deal for Array BioPharma, a drug developer that has seen its shares soar since announcing positive clinical trial results earlier this spring. Pfizer said Monday it will pay $48 per share in cash for Array, whose product portfolio includes a treatment combination used…
Psoriasis Treatment Market to Gain $121 Billion by 2024
As reported by TMR, the global psoriasis treatment market is prognosticated to exhibit a 5.10 percent CAGR over the forecast period from 2016 to 2024. The market was estimated to be worth $7.8 bn in 2015 and is forecasted to reach $12.1 bn by 2024. North America is predicted to emerge as the leading region…
ADHD Drugs Market Will Register a CAGR of Almost 6 Percent by 2023
The rising incidence rate of ADHD among children is one of the critical factors that will trigger the growth of the attention deficit hyperactivity disorder drugs market. The expansion of the patient pool with positive ADHD symptoms is fueling the demand for ADHD therapies. As per the CDC, in 2016. Approximately 9.4 percent of children…
FDA Approves First Chemotherapy Regimen for Relapsed Diffuse Large B-cell Lymphoma
Computational Biology Market Size Worth $13.6 Billion by 2026
Antifreeze Proteins Market Will Register a CAGR of Over 30 Percent by 2023
Impending Patent Cliff Threatens Billions of Global Prescription Drug Sales
Over $198 billion in global prescription drug sales are at risk between 2019-2024 from patent expirations, according to a new report from EvaluatePharma. Experts are now warning that the pharmaceutical industry is on the brink of a second patent cliff. Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842…
FDA Approves First Treatment for Episodic Cluster Headache
The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of the Division…
FDA Approves New Treatment for Hospital-acquired, Ventilator Associated Bacterial Pneumonia
The U.S. Food and Drug Administration approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections.…
Global Pulmonary Arterial Hypertension Market Size Expected to Reach $9.3 Billion by 2026
The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026. It is projected to progress at a CAGR of 5.6 percent during the forecast period. Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth. The cases of PAH…